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Abstract
In the interest of identification of new kinase-targeting chemotypes for target and pathway analysis and drug discovery in
Trypanosomal brucei, a high-throughput screen of 42,444 focused inhibitors from the GlaxoSmithKline screening collection
was performed against parasite cell cultures and counter-screened against human hepatocarcinoma (HepG2) cells. In this
way, we have identified 797 sub-micromolar inhibitors of T. brucei growth that are at least 100-fold selective over HepG2
cells. Importantly, 242 of these hit compounds acted rapidly in inhibiting cellular growth, 137 showed rapid cidality. A
variety of in silico and in vitro physicochemical and drug metabolism properties were assessed, and human kinase selectivity
data were obtained, and, based on these data, we prioritized three compounds for pharmacokinetic assessment and
demonstrated parasitological cure of a murine bloodstream infection of T. brucei rhodesiense with one of these compounds
(NEU-1053). This work represents a successful implementation of a unique industrial-academic collaboration model aimed at
identification of high quality inhibitors that will provide the parasitology community with chemical matter that can be
utilized to develop kinase-targeting tool compounds. Furthermore these results are expected to provide rich starting points
for discovery of kinase-targeting tool compounds for T. brucei, and new HAT therapeutics discovery programs.
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Introduction
Human African trypanosomiasis (HAT) is a parasitic infection
that affects 10,000 patients annually 1]. Current therapies for
HAT have significant issues of toxicity, inconvenient dosing
regimens, and emerging resistance. While there are new thera-
peutic options currently being evaluated in the drug development
pipeline, such as SCYX–7158 2], nifurtimox-eflornithine combi-
nation therapy 3], and fexinidazole 4,5], there remains a need for
back-up approaches to new drugs for this disease.
In recent years, in response to repeated calls for new drugs from
the World Health Organization and clear guidelines for new drug
specifications for HAT 6], drug discovery efforts have increased
worldwide for this otherwise neglected disease. The acute lack of
financial incentive for undertaking the costly drug discovery
process is increasingly being addressed by a combination of public
research funding, as well as philanthropic and industrial contri-
butions. The OpenLab Foundation was established in 2010 as
a means to provide financial support to drug discovery efforts
performed at GlaxoSmithKline (GSK) in collaboration with
investigators outside the company who have identified new
approaches to fighting tuberculosis 7], and tropical diseases such
as HAT, malaria 8,9], Chagas disease, and leishmaniasis. Indeed,
in recent years large sets of screening data for compounds tested
against the pathogens causing these diseases have emerged from
this unique combination of industrial, philanthropic, and non-
industrial collaborators 7,8].
One powerful approach to discovery of new drugs for HAT has
been directed at repurposing established knowledge about classes
of molecular targets that the pathogen holds in common with








humans, recognizing that the huge body of historical knowledge
around homologous targets could be quickly redirected to
inhibiting pathogen growth 10]. These target families include
phosphodiesterases 11], histone deacetylases 12], and kinases
13,14,15,16,17].
T. brucei expresses 176 kinases 18,19], an observation that has
driven our efforts to identify classes of kinase inhibitors that can be
useful for discovery of new parasite growth inhibitors. For
example, we recently reported that the human PI3K and mTOR
inhibitor NVP-BEZ235, a Phase III clinical candidate for solid
tumors, is highly potent against trypanosomes in culture and in
vivo 14]. Other PI3K and mTOR inhibitors were also shown to be
potent lead compounds for killing trypanosomatid parasites.
Recognizing that we had only tested a very small fraction of the
kinase inhibitor chemotype space, and that the kinome of T.
brucei, Leishmania, and T. cruzi have been analyzed and found to
have moderate similarity to human kinases 18], we hypothesized
that testing a much wider set of human kinase inhibitor
chemotypes should allow identification of a wide range of starting
points for HAT therapeutics.
Over the last few decades, drug discovery efforts have focused
on discovery of inhibitors for specific molecular targets (enzymes,
receptors), though it is now becoming apparent that combining
whole-cell activity data with molecular mechanism of action
information is, in fact, the most productive path forward to new
discovery 20]. Further, since little detail is known about the
functions of the T. brucei kinome, the discovery of putative kinase-
targeting inhibitors that potently inhibit cell growth represent an
opportunity not only for new leads for HAT, but also new tool
compounds for elucidation of kinase function in the pathogen.
With this in mind, we now report the assessment of 42,444
kinase-targeted compounds in a high-throughput, cell-based T.
brucei growth assay, followed by evaluation of cellular selectivity,
characterization of the rate and reversibility of action, coupled
with a range of predictive and experimental determinations of
drug-like properties that can inform prioritization for future drug
discovery efforts for HAT. To our knowledge, this represents the
largest kinase-targeted HTS against T. brucei, resulting in
discovery of 797 validated T. brucei growth inhibitors, grouped
into 59 clusters (plus 53 singleton compounds), intended to prompt
new studies of mechanism of action and further pursuit for drug
optimization for HAT. We further describe the prioritization of 46
clusters based on potency, rate-of-action, cidality, and predicted
central nervous system (CNS) exposure. The progression through




Single concentration screening assay (primary HTS
campaign). Greiner sterile black clear bottom 384-well assay
plates were pre-dispensing with 200 nL of compound in each well,
from master plates at 1 mM (100% DMSO) containing selection
from the GSK compound collection. Controls of 0% response
(control 1, 200 nL of 100%DMSO) and 100% response (control 2,
200 nL of 1 mM pentamidine) were included in each assay plate
in columns 6 and 18, respectively. Plates containing 200 nL of
100% DMSO were included randomly in the assay, to assess
quality through all process. To detect growth inhibition, T. brucei
brucei parasites (Lister 427 strain) in log phase were diluted to a
Figure 1. The project assay cascade.
doi:10.1371/journal.pntd.0003253.g001
Author Summary
Human African trypanosomiasis, or sleeping sickness,
affects 10,000 patients annually, yet current drugs for this
disease are poor, with high toxicity and inconvenient
dosing requirements. Trypanosoma brucei, the parasite
that causes sleeping sickness, is sensitive to a class of
compounds called kinase inhibitors, and our project was
aimed at identifying kinase-targeting compounds that
rapidly and irreversibly inhibit parasite growth. This was
accomplished by high-throughput screening of over
42,000 compounds, which resulted in identification of
797 potent inhibitors of parasite growth that are non-toxic
to human cells. These inhibitors were studied for the speed
of their effects and reversibility of growth inhibition, and
were grouped on the basis of chemical structure similarity.
One compound was shown to cure mice from a
bloodstream of infection of T. brucei. These compounds
can now be utilized by the research community as starting
points for new drug discovery, and also as tool com-
pounds for understanding the function of kinases in T.
brucei.
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working concentration of 2,500 cells/mL in prewarmed HMI-9
medium, and gently stirred until dispensation. 50 mL of culture
were dispensed in compound-stamped black, clear-bottom 384-
well Greiner microplates using a Multidrop Combi Reagent
Dispenser (Thermo Scientific), to give a final solvent concentration
of 0.4% DMSO. Plates were covered with lid and cells were
incubated for 70 hours at 37uC and 5% CO2. After this period,
10 mL of 200 mM resazurin solution in prewarmed HMI-9 were
added to each well, and plates were allowed to incubate 2 hours
more prior fluorescence reading in a Wallac EnVision Multilabel
Plate Reader (Perkin-Elmer). Raw fluorescent data from the
Envision plate reader were uploaded into GSK HTS database
(ActivityBase). Activity of each well was normalized as a percentage
of inhibition per-plate basis using the following equation:
%Inhibition~100{
100  Test well-Median CTRL1
Median CTRL1-Median CTRL2
Where control 1 represents wells from the same plate containing
0.4%1DMSO (0% inhibition, 100% grown control, n = 16), and
control 2 represents wells from the same plate treated with
Pentamidine (100% inhibition, 0% grown, n = 16). A Z9 value
greater than 0.4 was required for plate validation during the
quality control process.
Dose response assay. For dose-response experiments, serial
compound dilutions of selected hits from the primary campaign
were plotted against compound concentration. Dose response
master plates were prepared by 3-fold dilutions (starting with
10 mM DMSO stock solutions), providing 11 concentrations.
From these master plates, 200 nL per well was stamped in final
assay plates, including the same controls describe in the primary
single shot assay. Compounds were dispensed as serial dilution
curve format, with 11 points at 3-fold dilution and 40 mM as
starting top concentration (n = 2). Growth inhibition assay was
performed as described in previous assay.
A 4-parameter equation describing a sigmoidal dose-response
curve was then fitted with an adjustable baseline using Activity-
Base XE Runner software. Fitting of dose-response curves and
EC50 determination were normalized as percentage of inhibition







Cytotoxicity assay. This assay was used as selectivity assay,
and selected hits from the primary were test in dose response
concentration against HepG2 in order to identify the level of host
cell cytotoxicity. Dose response starting at 10 mM and with 3-fold
dilutions for 11 points, were made in 1,536-well master plates.
50 nL per well from them were stamped in final assay plates. The
human biological samples were sourced ethically and their
research use was in accord with the terms of informed consent.
Log-phase HepG2 cells were removed from a T-175 TC flask
using Cell Dispersion Medium and dispersed by repeated
pipetting. Cell density was adjusted to 60,000 cells/mL as working
concentration in prewarmed Eagle’s MEM medium. Seeding
density was be checked to ensure that new monolayers are not
more than , 50% confluent at the time of seeding (typically 3,000
cells per well), before completing preparation of plates. 5 mL of
culture were dispensed in compound-stamped TC treated, Greiner
white 1,536-well plates using a Multidrop Combi Reagent
Dispenser (Thermo Scientific), to a final concentration of 2.5%
DMSO. Cells were incubated for 48 hours at 37uC and 5%CO2.
Viability was determined by Cell Titer Glo Kit (Promega)
according to manufacturer’s instructions: briefly, reconstituted
Cell Titer Buffer was equilibrated to room temperature prior its
use and 5 mL per well were dispensed with a Multidrop Combi
Reagent Dispenser. Contents were mixed on a plate orbital shaker
and incubated for 10 min at room temperature, to allow the signal
to stabilize before luminescence reading on ViewLux Plate Reader
(Perkin-Elmer).
Raw Luminescence data from the ViewLux reader were
uploaded into GSK HTS database (ActivityBase). Activity of each
well was normalized as a percentage of inhibition per-plate basis




Where control 1 represents wells from the same plate containing
1% DMSO (0% inhibition, 100% grown control, n = 128), and
control 2 represents wells from the same plate treated with
Digitoxin (100% inhibition, 0% grown, n = 128). A Z9 value
greater than 0.4 was required for plate validation during the
quality control process.
As previously described for the primary assay, a 4-parameter
equation describing a sigmoidal dose-response curve was then
fitted with an adjustable baseline using ActvityBase XE Runner
software.
Rate of action assays. Serial compound dilution of selected
hits from single concentration screening assay, starting at 10 mM
and with 3-fold dilutions for 11 points, were made in master plates.
From these master plates, 30 nL per well were stamped in final
assay plates Greiner 1,536-well Solid White, including controls of
0% response (DMSO) and 100% response (40 mM pentamidine):
compound final assay top concentration was 40 mM. 8 mL of T.
brucei culture in log phase were dispensed on assay plates using a
Multidrop Combi Reagent Dispenser (Thermo Scientific), after
adjusting cell density according to the different incubation time
points described in the text; 4 sets of compound plates were
arranged to assay in order to be sequentially stopped at their
correspondent time point, and plates containing DMSO were
included randomly in the assay, to assess quality through all
process. Plates were incubated at 37uC and 5% CO2 for the
indicated time points; incubation was stopped by addition of 2 mL
of Cell Titer Glo reagent (Promega), and after shaking the plates
were incubated at room temperature for 30 min, to allow the
signal to settle. Plate luminescence was read on a ViewLux
multiplate reader (Perkin Elmer), and raw data were processed and
analyzed with ActivityBase software. As previously described
percentage of inhibition was calculated for each concentration
based on controls. A 4-parameter equation was used to fit the
dose-response curves and pEC50 determination.
Reversibility assays. Serial compound dilution of selected
hits from rate of action assay, starting at 10 mM and with 3-fold
dilutions for 11 points, were made in master plates. 100 nL per
well from master plates were stamped in final assay black, clear-
bottom 384-well Greiner microplates, including controls of 0%
response (DMSO) and 100% response (2 mM Pentamidine): the
final assay concentration was 20 mM. Plates containing DMSO
were included randomly in the assay, to assess quality through all
process. T. brucei cells in log phase were diluted to a working cell
density of 3,000 cells/mL, and culture was dispensed in assay
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plates using a Multidrop Combi Reagent Dispenser (Thermo
Scientific), while gently stirred; after dispensation, plates were
covered with lid and incubated at 37uC and 5%CO2. After
18 hours incubation, plates were centrifuged in a centrifuge
(Beckman Coulter) for 5 min at 500 g, to sediment the cells,
supernatant was aspirated with a Cybio-Well dispenser (Cybio),
and 40 mL/well of fresh prewarmed HMI-9 were added: this cycle
was performed three times. After the last cycle, 10 mL/well of cells
suspension were aspirated by Cybio-Well equipment and dis-
pensed over 40 mL of fresh prewarmed HMI-9 in ‘‘recovery
plates’’: calculated maximal residual concentration was 32 nM.
The recovery plates were incubated for 70 hours at 37uC and
5%CO2: after this period, 10 mL of 200 mM resazurin solution in
prewarmed HMI-9 were added to each well, and plates were
allowed to incubate 2 hours more prior fluorescence reading in a
Wallac EnVision Multilabel Plate Reader (Perkin-Elmer). Assay
stadistical quality was determined by Z’ score and validated data
set were analyzed with ActivityBase software. As previous
described percentage of inhibition was calculate for each
concentration based on controls. A 4-parameter equation was
used to fit the dose-response curves and pEC50 determination. The
potential effect of residual drug remaining after washes was
evaluated by performing the same protocol with standard
trypanocidal drugs (such as suramin and diminazene) and
negligible effect was observed.
ADME and physicochemical properties assays
CLND kinetic solubility assay. 5 mL of 10 mM DMSO
stock solution was diluted to 100 mL with pH 7.4 phosphate
buffered saline, equilibrated for 1 hour at room temperature,
filtered through Millipore MultiscreenHTS-PCF filter plates (MSSL
BPC). The filtrate was quantified by suitably calibrated flow
injection Chemi-Luminescent Nitrogen Detection 21]. The
standard error of the CLND solubility determination is
630 mM, the upper limit of the solubility is 500 mM when
working from 10 mM DMSO stock solution.
GSK in-house artificial membrane permeability
assay. A 1.8% lipid (phosphatidyl choline, egg) in 1% choles-
terol decane solution was applied to a Millicell 96-well, 0.4 mm,
PCF culture plate. 250 mL and 100 mL 50 mM phosphate buffer
pH 7.4 with 0.5% encapsin was applied to the donor and receiver
compartments, respectively. 2.5 L of a 10 mM stock solution of
compound in DMSO was added to the donor compartment. The
assay was incubated at RT for 3 hours. Samples from both donor
and receiver compartments were analyzed by HPLC with UV
detection at 215 and 254 nm and permeability was calculated.
The permeability (logPapp) measures how fast molecules pass
through the lipid membrane is expressed in nm/s.
ChromlogD assay. The Chromatographic Hydrophobicity
Index (CHI)22] values were measured using reversed phase HPLC
column (Luna C18 (2), Phenomenex, UK) with a fast acetonitrile
gradient at starting mobile phase of pH = 7.4. CHI values are
derived directly from the gradient retention times by using a
calibration line obtained for standard compounds. The CHI value
approximates to the volume % organic concentration when the
compound elutes. CHI is linearly transformed into ChromlogD by
least-square fitting of experimental CHI values to calculated ClogP
values for over 20,000 research compounds using the following
formula: ChromlogD = 0.0857CHI-2.00. The average error of
the assay is 63 CHI unit or 60.25 ChromlogD.
Protein binding assay. Chemically bonded Human Serum
Albumin (HSA) and Alpha-1-acidglycoprotein HPLC stationary
phases (Chiral Technologies, France) were used for measuring
compounds’ binding to plasma proteins, applying linear gradient
elution up to 30% iso-propanol. The run time was 6 min,
including the re-equilibration of the stationary phases with the
50 mM pH7.4 ammonium acetate buffer. The obtained gradient
retention times were standardised using a calibration set of
mixtures as described in the references 23]. The average standard
error of the assay depends on the binding strength and kinetics of
the compounds. It ranges from65% in the medium binding range
which reduces to 0.1% at binding above 99% with fast kinetics.
Phospholipid binding assay (IAM). Compounds binding to
immobilized artificial membrane (IAM) has been measured using
commercially available IAM PC DD (Regis Analytical, West
Lafayette, USA) HPLC column. Applying acetonitrile gradient up
to 70% the gradient retention times of the compounds were
converted to Chromatographic Hydrophobicity Indices (CHI
IAM) using a calibration set of compounds. The CHI IAM values
then were converted to the logarithmic retention factors using the
following formula, obtained from the correlation of isocratic and
gradient retention time 24]:
log k IAM = 0.046*CHI IAM+0.42,
Cytochrome P450 (CYP450). The P450 inhibition profile of
the inhibitors was determined as previously described [25].
In vivo experiments
Ethics statement. Efficacy experiments: Guidelines of the
European Convention for the Protection of Vertebrate Animals
used for Experimental and other Scientific Purposes (CETS #123)
were applied to maintain and care of mice used in this work. The
animal experimental protocol CEEA2013/MNC/2 used for
African trypanosome studies was reviewed and approved by the
Ethical Committee of the Instituto de Parasitologı´a y Biomedicina
‘‘Lo´pez Neyra’’ and the Ethical Committee of the Spanish
National Research Council (CSIC). Pharmacokinetic experiments:
All experiments were approved by the Diseases of the Developing
World (DDW-GSK) ethical committee, and performed under
protocol number AP1925v2. All animal studies were ethically
reviewed and carried out in accordance with European Directive
2010/63/EU, Spanish legislation RD53/2013, and the GSK
Policy on the Care, Welfare and Treatment of Animals.
Mouse pharmacokinetics. For pharmacokinetic studies
NMRI female mice of 20–25 g weight were used. Experimental
compounds were administered by the following routes at a volume
of 10 mL/kg (n = 3 mice per route): compound NEU-1200,
intravenous (iv) bolus at 1 mg/kg and intraperitoneal (ip) bolus at
5 mg/kg. Compounds NEU-1207 and NEU-1053, iv bolus at
1 mg/kg, ip bolus at 5 mg/kg and by oral gavage (po) at 5 mg/kg.
All mice received treatment in the fed state. Drugs were
administered as solution in the following vehicles: NEU-1200,
Saline (pH adjusted to 4.8); NEU-1207, 20% Encapsin/5%
DMSO in saline solution; NEU-1053, 20% Encapsin/5%
DMSO/7.5% PEG400 in saline solution.
Peripheral total blood was the compartment chosen for the
establishment of compound concentrations. Aliquots of 20 mL of
blood was taken from the lateral tail vein for each mouse at the
following time points post-dose: for iv and ip route, 5, 15 and
30 min, 1, 2, 4, 6 and 8 h; for po route, 15, 30 and 45 min, 1, 2, 4,
6 and 8 h.
LC-MS was used as the analytical method of choice for the
establishment of compound concentration in blood with a
sensitivity of LLQ = 1–5 ng/ml in 20 mL of blood. The non-
compartmental data analysis (NCA) was performed with Win-
Nonlin Phoenix 6.3 (Pharsight, Certara L.P) and supplementary
analysis was performed with GraphPad Prism 6 (GraphPad
Software, Inc). The pharmacokinetic parameters are shown in
tabular format in the Supporting Information, Table S7.
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In vivo efficacy experiments. Stock solutions (30 mg/mL)
of NEU-1053 were prepared in DMSO, with the final concen-
tration #6.3% DMSO, a concentration that did not exhibit any
toxicity for the parasite or mice. For treatment, NEU-1053 was
prepared in PBS (Sigma-Aldrich) and then heated at 50uC for
10 min to solubilize.
Female NMRI mice were obtained from Charles River
Laboratories and were kept in a conventional room at 20–24uC
with a 12/12-h light/dark cycle. The animals were provided with
sterilized water and were fed ad libitum. Infection was performed
by i.p. injection of 104 bloodstream forms of T. b. rhodesiense
(EATRO3 ETat1.2 TREU164) or T. b. brucei (Lister 427) strain
in 0.2 mL TDB glucose. Three days later, infected animals with
confirmed parasitemia were divided into two equal groups:
Control (infected mice, and treated with the vehicle DMSO
(6.3% in PBS)); and Drug-treated (infected mice treated with 2
doses of 10 mg of drug per kg of body weight per day (20 mg/kg/
d)). Four mice in each group were used in this assay. Drug-treated
mice received a 0.2 mL ip injection at the 3rd day from infection
during 4 consecutive days. After a 4 day hiatus, drug was
administered for additional 4 days.
Parasitemia was individually checked by direct microscopic
counting of parasites in a Neubauer chamber using 2 mL of blood
from infected mice tail, diluted in 500 mL of TDB glucose. In
order to increase the sensitivity of parasite detection, the collected
blood was diluted in 20 mL HMI-9 medium, distributed in a 96
well plate (Thermo Scientific) and was incubated at 37uC and 5%
CO2. In addition, a 2006 dilution of the initial 20 mL was also
monitored for parasite growth. This strategy allowed us an
improved parasitemia detection (500 parasites/mL of blood).
Mortality was examined daily until 90 days post-infection and
expressed as a percentage of cumulative survival.
Results
Compound library selection
A kinase inhibitor subset was selected to be screened in the
growth assay using three approaches. First, compounds from the
GSK compound screening collection that possess.70% Tanimoto
similarity to the previously-reported active PI3K/mTOR inhibitor
chemotypes 14] were selected (2,979 compounds). Second, we
included the GSK Published Kinase Inhibitor Set (367 com-
pounds) 26]. Third, we included the subset of 39,098 kinase
inhibitor compounds from the wider screening collection to create
a full 42,444 member kinase-targeted library.
High-throughput screening
A high-throughput screen (HTS) was developed using a T. b.
brucei (Lister 427 strain) whole-cell assay based on a widely-
validated resazurin viability test 27] in HTS format. During assay
development, final experimental conditions were assessed in terms
of DMSO and compound concentration, inoculum density and
resazurin-dependent fluorescence, and validated with standard
trypanocidal drugs and kinase inhibitors 14,28]. The selected
compounds from the GSK collection were tested at 4 mM
concentration in a single point assay to test their growth inhibition
in a log-phase culture of T. b. brucei using the optimized assay
conditions. The HTS was performed in 384-well format, with a Z9
robust value mean of 0.78, a mean signal-to-background. 5 and a
throughput of ,17,600 compounds per day 29]. Representative
HTS performance metrics are available in Figure 2, and
additional details are described in the Supporting Information.
Approximately 15% of the original set (6368 out of 42,444)
displayed more than 50% growth inhibition at 4 mM drug
concentration in the HTS close to the robust statistical cut-off (3
SD). These compounds were subjected to a confirmatory single
concentration assay, and tested in duplicate sets, leading to 4,574
compounds to be advanced to T. brucei and HepG2 cell dose-
response assays. We selected a relatively short incubation time for
the HepG2 cell assay (24-48 hours) to allow identification of
compounds with acute host cell toxicity. Taking these assays
together, we found 797 compounds to have EC50 values #1 mM
against T. brucei cells, with at least 100-fold selectivity over
HepG2 cells.
Analysis of compound properties
Ligand efficiency (LE) is a characterization of a compound’s
efficiency on a per-heavy-atom basis. Calculated by 1.37*pEC50
divided by the number of heavy atoms, a value of LE $0.3 is
typically accepted as a good starting point for optimization efforts
30]. Although ligand efficiencies come from a thermodynamic
analysis of target-ligand interactions, we use them here as a score
or descriptor to prioritize compounds based on their balance of
activity vs molecular size and lipophilicity. LE is most commonly
utilized in analysis of target-based assay results, but, as demon-
strated in a recent antimalarial program, it can be utilized to
normalize potency for molecular size in cell assays as well 31]. Of
the 797 hit compounds, 538 (or 68%) show an LE.0.3
(Figure 3A). The cLogP and molecular weight of the hits are
plotted in Figure 3B, color coded for compounds that are
predicted to permeate the CNS based on a predictive model (vide
Figure 2. (A) Z trend over single shot campaign duration. (B) Distribution of %inhibition response in single shot assay. Plates assayed were run
on 3 different days, identified by different colors in plots A and B. (C) Correlation of 4,574 compounds in dose response assay (n = 2).
doi:10.1371/journal.pntd.0003253.g002
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infra). Lipophilic ligand efficiency (LLE, pEC50-cLogP) has
recently been shown to be reliable and meaningful metric of
inhibitor quality 32,33], with a targeted LLE$4 34]. Of the hit
compounds, 200 (25%) show an LLE value of at least 4, and 242
compounds (30% of the hits) have a LLE value between 3–4.
Computed properties of the hit compounds, as a comparison to
the overall screening set are shown in Figure 4 and are
summarized in Table 1. The distributions of the potent and
specific compounds are narrower, compared to the overall
screening set, with mean values slightly increased when compared
to the whole HTS set.
Noting that new HAT therapeutics must be centrally-acting, we
then computationally characterized the hit compounds for predict-
ed central nervous system (CNS) activity. We applied the method
recently disclosed by Wager et al. that utilizes commonly computed
properties (cLogP, cLogD, molecular weight, topological polar
surface area (TPSA), hydrogen bond donors, and pKa) to predict
each compound’s likelihood of CNS activity 35]. In this model,
preferred ranges for each of the properties above are identified,
compounds are scored based on compliance with each of those
property ranges, and these properties scores are summed to obtain
the CNS multiparameter optimization (MPO) score. Using this
method, compounds with a CNS MPO score of 4 or higher is
predicted to be centrally acting. (We note that one difference
between our MPO calculation and that performed by Wager et al. is
the method for computation of pKa. We utilized the pKa
computation from ChemAxon, whereas previous work utilized that
available from ACD/Labs). Figure 3B shows a plot of cLogP
versus molecular weight of the 797 potent and selective compounds;
329 compounds (41% of the total) have a MPO score $4 (green),
and are predicted to have a high propensity for CNS activity.
Rate-of-action and cidal/static studies
In order to identify the most effective anti-trypanosomal agent, we
sought compounds that would rapidly (#18 hours) and irreversibly
kill T. brucei cells. While the initial assays above were carried out at
72 h using resazurin as a redox indicator of cellular viability and
density, we performed a different cell viability dose-response assay at
shortened compound-treatment periods (6, 12, 18 and 24 h) 2]. For
these experiments we utilized ATP content as an indicator of living
cells, which achieves a lower level of detection than the resazurin
assay 36]. This allowed us to use lower cell densities to quantify cell
death as signal decay. We note that the different readout had no
effect upon compound potency at 72 hours.
Since cell density remains almost invariable for 6 hours of
incubation, the biological activity of compounds near this time
Figure 3. Representation of 797 hit compounds. (a) Plot of LLE vs
LE, color coded based on MPO score (min= 1.1, Red; max = 5.75, Green).
(b) plot of molecular weight vs cLogP. Compounds with MPO score $4
are colored green.
doi:10.1371/journal.pntd.0003253.g003
Figure 4. Histogram distributions of cLogP, MW and TPSA for (a) the whole HTS set (42,444 compounds, red), and (b) the 797
potent and specific compounds (pEC50.6 and 100-fold specificity, blue).
doi:10.1371/journal.pntd.0003253.g004
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point predominantly reflects induction of cell death. However, at
incubation times.24 hours, when cell density has significantly
increased, the action of compounds almost exclusively reflects
growth inhibition. Thus, assessment of cell density at intermediate
incubation times (i.e. 12 and 18 hours) can allow us to discern
between compounds that act via cell killing or via growth
inhibition. Compounds that do not quickly kill the parasite or
arrest its growth will appear inactive at 6 hours in the ATP content
assay and active at 72 hours in the resazurin-based one.
Conversely, compounds with a rapid action will already exhibit
their effects at short (6 hour) incubation times, with increasing
potency with longer incubation times.
Table 1. Summary of average properties of the overall
screening set and specific compounds.
Mean values
HTS Set (n =46,688) Hits (n =797) D
cLogP 3.24 3.55 0.31
MW 372.28 395.12 22.84
TPSA 81.27 96.53 15.26
doi:10.1371/journal.pntd.0003253.t001
Figure 5. Rate-of-action curves for 797 potent T. brucei growth inhibitors, shape-clustered. Average rate-of-action within a given cluster is
shown as a polynomial fit to the curves (black). Curves for rapidly acting compounds (pEC50.6 at 18 h) are depicted in dark blue.
doi:10.1371/journal.pntd.0003253.g005
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With this analysis in mind, the pEC50 values for each compound
were plotted as a function of time, generating rate-of-action
curves, which were shape-clustered into 11 clusters by using a K-
means algorithm with Euclidean distances (Figure 5). The
average shape of the curves in each cluster (the black curves in
Figure 5) was delineated by fitting a third degree polynomial to
all the points in each cluster, allowing classification of the curve
clusters, such that different clusters display different rate of action
behavior. For instance, slow-acting compounds (pEC50$6 only
after 72 hours) are contained mainly in clusters 1, 4 and 7. Fast-
acting compounds are contained mainly in clusters 8–11, where
pEC50$6 was achieved as early as 12 hours of incubation time.
The remaining clusters show intermediate behaviors, with a
moderate but consistent increase in potency with increasing
incubation time. Thus, 242 compounds showed a pEC50$6 by
18 hours of incubation, were classified ‘‘rapidly acting’’ com-
pounds and are shown as dark blue curves in Figure 5.
We selected these rapidly-acting molecules for progression into
compound washout studies to determine their cidal/static
properties, and also tested 46 slower-acting compounds that
possessed computed properties consistent with good CNS
penetration (CNS MPO score$4). Dose-response assays were
performed as above, but, after 18 hours of incubation, drugs
were washed from the cell cultures. The resazurin cell viability
assay was performed 72 h after drug removal to determine the
extent to which the cells were able to resume replication and
growth. We defined the minimum trypanocidal concentration
(MTC, EC99) as the compound concentration that abolishes 99%
of growth recovery when compared with DMSO controls. We
define ‘‘cidal’’ compounds to be those with pEC99.6 after 18 hours
of incubation.
By this definition, 56% (or 137) of these rapidly acting
compounds are cidal. Within this set, 24 compounds achieved
pEC99 values.7. Further analysis also revealed that 96% of the
slow acting compounds that were included in these cidality assays
were static in behavior. Stated differently, fast acting rate-of-
action clusters (clusters 8–11) contain compounds that are
predominantly cidal, while other clusters are predominantly
static (Figure 6).
Selection and computation of properties for prioritization
At this point we performed a series of computations that would
help further prioritize these compounds in combination with the
CNS MPO scores described above.
We decided that a multi-factorial prioritization of screening hits
was warranted with a focus on specific properties that we decided
would be most valuable for selection of the most promising
chemotypes for future hit-to-lead optimization. We developed a
Composite Score that consisted of potency, ligand efficiency,
lipophilic efficiency, rate of action, and the cidal/static nature of
the inhibitor. These criteria were selected on the basis of the
desired properties for HAT therapeutic candidates (prioritizing
potent, fast-acting, cidal, and predicted brain-penetrant com-
pounds). The relative scoring was designed with this in mind, and
based on our collective drug discovery experience. Under this
scheme, the maximal score was 16, calculated as shown in
Table 2. For example, compounds with pEC50$8 scored 3
points, those between 7–8, 2 points, and between 6–7, 1 point.
Compounds that were rapidly acting (pEC50.6 at 18 hours)
received 2 points, and those whose pEC99 of 6 or greater received
2 points. We used a similar approach for scoring predicted CNS
activity (MPO Scores), and compound efficiencies (LE, LLE).
Points were totaled for each compound, providing the Composite
Score. Table S5 in the Supporting Information shows the
distribution of the HTS hits in each of the Composite Scoring bins.
Compound clustering
Compounds were visually grouped on the basis of common
substructures, which resulted in the delineation of 59 clusters. Of
these clusters, 46 clusters had at least one molecule with a composite
score of at least 6. Figures 7 and 8 shows the best-scoring
representatives of each of these 46 clusters. Structures of the 13 top-
scoring singleton compounds are shown in Figure 9, and a
summary of their measured and computed data is tabulated in the
Supporting Information (Table S2).
The Supporting Information (Table S1) tabulates average values
of key molecular properties for each compound cluster, along with
metrics regarding the percentage of each cluster that is fast killing
and/or cidal. This allows easy sorting of the compound clusters for
prioritization of hit-to-lead medicinal chemistry follow-up.
Kinase selectivity screening
We selected nine of the high-potency cluster representatives
shown in Figures 7 and 8 for assessment against 15 human
Figure 6. Scatter plot showing the average pEC50 at the
18 hour time point for the 242 compounds tested in the
cidality assay. Compounds are colored on the basis of reversibility
behavior (cidal = red; static = green).
doi:10.1371/journal.pntd.0003253.g006
Table 2. Compound composite scoring schema.
Score
3 2 1 0
pEC50 $8 8.x$7 7.x$6
Rate of actiona Fast Slow
MPO Score $5 3#x,5 1#x,3 ,1
Cidalb Yes No
LE $0.4 0.4.x$0.3 ,0.3
LLE $6 6.x$5 5.x$4 ,4
a‘‘Fast’’ is defined as pEC50$6 at 18 h.
b‘‘Cidal’’ is defined as pEC99$6 in the reversibility experiments. Only
compounds that were rapidly acting and/or had an MPO score $4 were tested
in the cidality assay; compounds not tested in the cidal assay are assigned a
score of 0.
doi:10.1371/journal.pntd.0003253.t002
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Figure 7. Highest-ranking cluster representatives for clusters 1-24. Each compound’s composite score is shown in parentheses.
doi:10.1371/journal.pntd.0003253.g007
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kinases in order to ascertain information about potential selectivity
liabilities. These kinases were chosen for general selectivity
screening owing to their broad representation of the human
kinome. The results are shown in the Supporting Information
(Table S3).
ADME properties screening
In addition to the computed chemical properties that are often
predictive of ADME properties, we mined the GSK database for
ADME properties for the hit compounds, and generated this data
for the most promising hits when it was not available. We tabulate
Figure 8. Highest-ranking cluster representatives for clusters 25-46. (Clusters 47-59 only contain compounds with composite scores ,6).
Each compound’s composite score is shown in parentheses.
doi:10.1371/journal.pntd.0003253.g008
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this data, where available, for the 46 cluster representatives
highlighted in the Supporting Information, Table S4.
Mouse pharmacokinetic assessments
We selected three of the most attractive hit compounds to be
assessed in mouse pharmacokinetic experiments, with an eye
towards selecting at least one to test in an in vivo model of HAT.
We selected NEU-1200 (cluster 32, composite score 13), NEU-
1207 (cluster 34, composite score 13), and the top-scoring
singleton NEU-1053 (composite score 12). The results of these
experiments are shown in Figure 10A, and the pharmacokinetic
parameters obtained are tabulated in the Supporting Information
(Tables S7). Of these three, NEU-1053 was selected for
assessment in the mouse bloodstream model of HAT on the basis
of its combination of high potency (T. b. brucei pEC50 = 9.17; T. b.
rhodesiense pEC50 = 9.6; T. b. gambiense pEC50 = 9.7, see Table
S6), rapid, cidal activity and excellent blood exposure following
intraperitoneal (ip) dosing (Figure 10A). The total blood exposure
was well in excess of the EC99 observed for the compound for.
24 hours, though we also observed a high plasma protein binding
(.99%) in human plasma. This led us to elect to use a higher dose
for the efficacy experiments.
Mouse efficacy model
We focused an in vivo efficacy experiment on NEU-1053 on the
basis of its excellent PK results and its very high in vitro potency.
We found this compound to be well-tolerated in mice at i.p. doses
of 20 mg/kg. In the bloodstream infection experiments (that
mimic Stage 1 HAT in humans), female NMRI mice were infected
with T. b. rhodesiense (EATRO3 ETat1.2 TREU164) on day 0,
and after three days, the infected animals were treated with
10 mg/kg doses of NEU-1053 twice a day for 4 days (days 3–6).
Following a four day hiatus, drug was administered for another
four days. On day 5, none of the mice treated with NEU-1053
showed any detectable parasitemia (Detection limit: 500 parasites/
mL of blood), while the control group showed parasitemia of 15-
940 million parasites/mL of blood (Supplementary Information
Table S9). Control mice succumbed to parasitemia on days 9-13
(80% on days 9–10), while the treated group maintained
undetectable parasitemia, except one of them, which had a peak
of parasitemia on day 11 (during the second round of treatment).
The rapid clearance of the parasitemia just 24–48 hours after
the first treatment suggests NEU-1053 has a potent trypanocidal
activity in vivo that is consistent with the rate of action and cidality
assays described above.
An identical in vivo experiment was performed using the highly
virulent strain of T. b. brucei (Lister 427). In this case, after day 3,
none of the mice treated showed any detectable parasitemia, while
the control group showed parasitemia of 520–1100 million
parasites/mL of blood (Supplementary Information Table S8).
All the control mice succumbed to parasitemia on day 5 (the third
day of the treatment). In contrast, the treated group maintained
undetectable parasitemia. After the four day treatment hiatus,
parasitemia was detected in 2 out of 4 mice. This second round of
treatment resulted again in a reduction of the parasitemia to
undetected levels for both positive mice.
We continued to follow parasitemia after the second four-day
regimen. One of the previously infected mice died on day 21, with
1.26108 parasites apparent in the blood on the day prior.
However, the three other mice have been deemed to be cured,
since 90 days after NEU-1053 treatment the mice are alive and no
parasitemia was detected.
In sum, while all the control mice succumbed to the infection,
all but one of the drug-treated mice showed parasitological cure
for 90 days following the drug treatment.
Discussion
Based on previous results in testing published investigational
human kinase inhibitors against T. brucei cultures and mouse
Figure 9. Representative singleton compounds with composite score $6. Each compound’s composite score is shown in parentheses.
doi:10.1371/journal.pntd.0003253.g009
Discovery of T. brucei Growth Inhibitors by Kinase-Targeted HTS
PLOS Neglected Tropical Diseases | www.plosntds.org 11 October 2014 | Volume 8 | Issue 10 | e3253
infections, we began considering whether a wider exploration of
novel kinase inhibitors could provide a more comprehensive set of
hit compounds that could afford a broad variety of kinase inhibitor
‘‘hits’’ that could be progressed into new leads for HAT
therapeutics discovery.
With this in mind, we selected 42,444 inhibitors from
GlaxoSmithKline’s compound collection on the basis of their
historical relevance to previous and ongoing kinase inhibitor drug
discovery programs within the company. In addition, we selected
compounds structurally similar to kinase inhibitors that we had
previously described to have anti-trypanosomal effects. Notably,
the HTS screening set contains the recently-disclosed Published
Kinase Inhibitor Set (PKIS) 37], which consists of 367 compounds
that GSK has profiled against a wide range of human kinase. We
will shortly report the entirety of the T. brucei cellular screening
data for this subset of the HTS.
The primary assay gave rise to a very large number of
compounds that inhibit parasite growth. This is evidence that
allows us to infer that perhaps kinase targeted libraries may be
biased towards high antiparasitic activity, and, since a significant
proportion are most likely operating via trypanosomal kinases, that
kinases represent a very powerful class of enzymes to target for
growth inhibitors.
The large hit rate we observed provided a unique opportunity to
critically evaluate and prioritize the hit compounds on the basis of
most desirable properties. We would expect that, based on
previous assertions that high-quality hits are most likely to result in
to high-quality leads and drugs 38], selecting the best hit
compounds from our screen would afford the best opportunity
for fruitful lead optimization later. Thus, we elected to prioritize
compounds on the basis of not only compound potency and
selectivity, but also on the basis of other critical predictors of
success for HAT therapeutics discovery, including predicted CNS
activity, good physicochemical properties, selectivity over human
kinases, as well as desirable cell action properties (rate of action
and cidality). These last two points are driven by the expectation
that compounds with a rapid and irreversible effect on parasite
sells would most likely be effective anti-HAT agents.
Since we have several variables of importance to new HAT lead
compounds, we implemented a multivariate Composite Scoring
system, similar to that utilized previously for antimalarial 8] and
anti-TB HTS hit series 7]. In developing a relative priority scoring
system, we have been able to rank order compounds, and clusters
of compounds, on the basis of their attractiveness for further study
and optimization.
As with any HTS campaign, the compounds identified here will
require hit-to-lead and lead optimization medicinal chemistry
efforts in order to translate into new clinical candidates. With this
in mind, we have provided additional data that allows the research
community to prioritize and direct follow-up on these hits. For
example, the in vitro ADME data shown in the Supporting
Information can be directive for identifying and rectifying
potential liabilities for a chemotype, such as solubility. Indeed,
the inclusion of such data for related compounds can allow
particularly useful comparisons.
Many of the compounds tested in this HTS emerged from
historical kinase inhibitor programs within GSK. It is not
surprising, therefore, that we observe a range of potency values
when selected compounds are tested against some human kinases.
This data will be useful for future optimization efforts by
highlighting potentially important human kinases for which it
may be desirable to reduce potency. However, it is not at all clear
that absolute selectivity over all human kinases is required (or even
achievable). It is possible that inhibition of some human kinases
Figure 10. (A) Peripheral blood levels of NEU-1200 (blue), NEU-
1207 (red) and NEU-1053 (green) after intraperitoneal admin-
istration of 5 mg/kg single dose to NMRI mice (n=3). The
average and standard deviation of the mean for each time point are
represented in the plot. Blood levels of NEU-1053 after IP administration
was observed till 24h post-dose. Y-axis is represented in log scale. (B)
Animal survival plot showing the effects of dosing of NEU-1053 (ip 20/
mg/kg/day; orange) versus DMSO control (black line) in T. b. brucei or
(C) T. b. rhodesiense infection. Parasitemia was checked on days
indicated by circles.
doi:10.1371/journal.pntd.0003253.g010
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during a short-duration HAT treatment may have little-to-no
toxicity effect.
Generally, it is expected that, following an HTS campaign, hit
compounds will need extensive optimization in order to achieve
efficacy in animal model proof-of-concept. In this case, however,
we were able to identify a compound, NEU-1053, which shows
profound effects in parasitemia reduction, leading to cure of
infection in mice. Based on its CNS MPO score, we expect that
this compound is unlikely to penetrate into the CNS (a
requirement for any new HAT clinical candidate), yet we believe
that this compound represents a powerful endorsement of the
whole cell high-throughput screening approach for antiparasitic
agents. Work is ongoing to identify potential mechanism(s) of
action for this compound, and analog synthesis campaigns are
underway to improve physicochemical properties that will enable
CNS penetration while maintaining potency.
There are additional, high-potency compounds in the screening
set that are currently undergoing PK studies and that, if these
results are indicative of good exposure, will be tested in infection
models. Also, we continue to look with keen interest in particular
at compounds that are predicted to show high CNS exposure;
following pharmacokinetic confirmation, such compounds will be
advanced into a CNS infection model of HAT. We anticipate
reporting such results in due course.
An essential feature of the project spawned at the GSK
OpenLab is the open availability of data to the wider neglected
disease research community. We have deposited the HTS data
shown in the tables within this report, along with human kinase
selectivity, physicochemical properties data, and computed prop-
erties in a shared data set at www.collaborativedrug.com and in
the ChEMBL database. This data is available to anyone who
wishes to access it in a searchable format. We encourage
collaborative pursuit of these chemical classes as starting points
for anti-T. brucei agents and we are open to address specific
queries on a particular series. In addition, since the kinomes of the
trypanosomatid parasites have been shown to be quite similar 19],
and since previous reports describe cross-reactivity of compounds
across related protozoan pathogens, these compounds may also
provide potential starting points for related parasites.
Supporting information available
Supplementary data tables are included in the Supporting
Information as noted throughout the text, annotated with NEU
registry numbers to enable online searching within the publically
available data set on www.collaborativedrug.com, and in the
ChEMBL database.
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